These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35608625)

  • 1. Urinary tract infection following intradetrusor onabotulinumtoxina injection for non-neurogenic urgency incontinence: single- vs. multi-dose prophylactic antibiotic treatment regimens.
    Crouss T; Kim Y; Lai E; Chopra V; Fagan M; Lipetskaia L
    Int Urogynecol J; 2023 Mar; 34(3):729-736. PubMed ID: 35608625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2013 Jun; 189(6):2186-93. PubMed ID: 23246476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the utility of routine urine culture and antibiotic treatment in children with neurogenic bladder undergoing intradetrusor OnabotulinumtoxinA injection.
    Bachtel HA; Flores H; Park B; Kim SJ; Koh CJ; Janzen NK
    J Pediatr Urol; 2023 Dec; 19(6):742.e1-742.e8. PubMed ID: 37537091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient perceived improvement and medication resumption rates after intradetrusor onabotulinumtoxina for idiopathic urgency urinary incontinence.
    Kocher NJ; Zillioux J; Goldman HB
    Int Urogynecol J; 2023 Mar; 34(3):745-749. PubMed ID: 35657395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).
    Yokoyama O; Honda M; Yamanishi T; Sekiguchi Y; Fujii K; Nakayama T; Mogi T
    Int J Urol; 2020 Mar; 27(3):227-234. PubMed ID: 31957922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
    Amundsen CL; Richter HE; Menefee SA; Komesu YM; Arya LA; Gregory WT; Myers DL; Zyczynski HM; Vasavada S; Nolen TL; Wallace D; Meikle SF
    JAMA; 2016 Oct; 316(13):1366-1374. PubMed ID: 27701661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Symptomatic Stress Urinary Incontinence on Catheterization Rates After Intradetrusor OnabotulinumtoxinA Injections.
    Brandon C; Pape DM; Oh C; Kreines FM; Thakker SS; Rosenblum N; Nitti VW; Brucker BM; Glass D
    Female Pelvic Med Reconstr Surg; 2021 Nov; 27(11):676-680. PubMed ID: 34009831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does symptom severity predict response to low-dose onabotulinumtoxinA for the treatment of urgency urinary incontinence?
    Gonzalez HM; Wheat JE; Dengler KL; Barbier HM; Gehrich AP; Gruber DD; Warner WB
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():118-124. PubMed ID: 33212321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
    Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
    J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder.
    Eckhardt SE; Takashima Y; Handler SJ; Tenggardjaja C; Yazdany T
    Int Urogynecol J; 2022 Mar; 33(3):703-709. PubMed ID: 33594517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder.
    DiCarlo-Meacham AM; Dengler KL; Welch EK; Brooks DI; Gruber DD; Osborn DJ; Scarlotta L; Vaccaro CM
    Neurourol Urodyn; 2023 Jan; 42(1):366-374. PubMed ID: 36455284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA-A secondary analysis.
    Guirguis Hanna M; Bradley M; Zyczynski H; Wang L; Giugale L
    Neurourol Urodyn; 2023 Aug; 42(6):1238-1244. PubMed ID: 37086398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.
    Elmer-Lyon CG; Streit JA; Takacs EB; Ten Eyck PP; Bradley CS
    Int Urogynecol J; 2020 May; 31(5):871-879. PubMed ID: 31222571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
    Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
    BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.
    Visco AG; Brubaker L; Richter HE; Nygaard I; Paraiso MF; Menefee SA; Schaffer J; Lowder J; Khandwala S; Sirls L; Spino C; Nolen TL; Wallace D; Meikle SF;
    N Engl J Med; 2012 Nov; 367(19):1803-13. PubMed ID: 23036134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
    Chuang YC; Kaufmann JH; Chancellor DD; Chancellor MB; Kuo HC
    J Urol; 2014 Dec; 192(6):1743-9. PubMed ID: 25046622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-centre experience with intradetrusor injection of onabotulinumtoxinA: a retrospective study of the years 2003-2012 in a Danish population.
    Christiansen FE; Pedersen TB; Juel J; Kirkeby HJ
    Scand J Urol; 2017 Oct; 51(5):392-396. PubMed ID: 28699369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.